Signal brief

CMI Media Group, a WPP unit, launched a Rare Disease Center of Excellence to deliver micro-precision audience targeting for niche therapies. The COE leverages AI, proprietary data, and partnerships with patient groups to streamline diagnosis and engagement in rare diseases, potentially expanding WPP's share of pharmaceutical marketing spend as rare-disease brands grow.

• CMI Media Group, a WPP unit, launches Rare Disease COE.
• COE targets micro-precision audience strategies for rare therapies using AI and data.
• Nearly 50% of new drug approvals are rare/orphan diseases.
• CMI has launched 67 rare-disease brands to date across multiple therapeutic areas.
• Partnership with Bionews Patient Advisory Board emphasizes patient-centric insights.